1. Chilamakuri, R, Agarwal, S. COVID-19: characteristics and therapeutics. Cells. 2021;10:206. doi:10.3390/cells10020206.
Google Scholar | Crossref | Medline2. Bettini, E, Locci, M. SARS-CoV-2 mRNA vaccines: immunological mechanism and beyond. Vaccines. 2021;9:147.
Google Scholar | Crossref3. Boyarsky, BJ, Werbel, WA, Avery, RK, et al. Antibody response to 2-Dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA. 2021;325:2204-2206.
Google Scholar | Crossref | Medline4. Cagigi, A, Loré, K. Immune responses induced by mRNA vaccination in mice, monkeys and humans. Vaccines. 2021;9:61.
Google Scholar | Crossref5. Conti, P, Caraffa, A, Gallenga, CE, et al. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem. J Biol Regul Homeost Agents. 2021;35:1-4.
Google Scholar | Medline6. Chu, L, McPhee, R, Huang, W, et al. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine. 2021;39:2791-2799.
Google Scholar | Crossref | Medline7. Bassi, F, Arbia, G, Falorsi, PD. Observed and estimated prevalence of Covid-19 in Italy: how to estimate the total cases from medical swabs data. Sci Total Environ. 2021;764:142799.
Google Scholar | Crossref | Medline8. Huff, HV, Singh, A. Asymptomatic transmission during the coronavirus disease 2019 pandemic and implications for public health strategies. Clin Infect Dis. 2020;71:2752-2756.
Google Scholar | Crossref | Medline9. Zhao, D, Wang, M, Wang, M, et al. Asymptomatic infection by SARS-CoV-2 in healthcare workers: a study in a large teaching hospital in Wuhan, China. Int J Infect Dis. 2020;99:219-225.
Google Scholar | Crossref | Medline10. Hou, X, Zaks, T, Langer, R, Dong, Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021. doi:10.1038/s41578-021-00358-0
Google Scholar | Crossref | Medline11. Laczkó, D, Hogan, MJ, Toulmin, SA, et al. A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice. Immunity. 2020;53:724-732.e7.
Google Scholar | Crossref | Medline12. Pardi, N, Hogan, MJ, Naradikian, MS, et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med. 2018;215:1571-1588.
Google Scholar | Crossref | Medline13. Crommelin, DJA, Anchordoquy, TJ, Volkin, DB, Jiskoot, W, Mastrobattista, E. Addressing the cold reality of mRNA vaccine stability. J Pharm Sci. 2021;110:997-1001.
Google Scholar | Crossref | Medline14. Karikó, K . In vitro-transcribed mRNA therapeutics: out of the shadows and into the spotlight. Mol Ther. 2019;27:691-692.
Google Scholar | Crossref | Medline15. Karikó, K, Muramatsu, H, Welsh, FA, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008;16:1833-1840.
Google Scholar | Crossref | Medline16. Anderson, EJ, Rouphael, NG, Widge, AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. New Engl J Med. 2020;383:2427-2438.
Google Scholar | Crossref | Medline17. Canaday, DH, Carias, L, Oyebanji, OA, et al. Reduced BNT162b2 mRNA vaccine response in SARS-CoV-2-naive nursing home residents. Clin Infect Dis. Published online March 22, 2021. doi:10.1101/2021.03.19.21253920
Google Scholar | Crossref18. Benotmane, I, Gautier-Vargas, G, Cognard, N, et al. Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients. Kidney Int. 2021;99:1487-1489.
Google Scholar | Crossref | Medline19. Abu Jabal, K, Ben-Amram, H, Beiruti, K, et al. Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021. Euro Surveill. 2021;26:2100096. doi: 10.2807/1560-7917.ES.2021.26.6.2100096
Google Scholar | Crossref | Medline20. Krammer, F, Srivastava, K, Alshammary, H, et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. New Engl J Med. 2021;384:1372-1374.
Google Scholar | Crossref | Medline21. Ebinger, JE, Fert-Bober, J, Printsev, I, et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med. 2021;27:981-984.
Google Scholar | Crossref | Medline22. Bradley, T, Grundberg, E, Selvarangan, R, et al. Antibody responses after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med. 2021;384:1959-1961.
Google Scholar | Crossref | Medline23. Callegaro, A, Borleri, D, Farina, C, et al. Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection. J Med Virol. 2021;93:4612-4615.
Google Scholar | Crossref | Medline24. Haddad, NS, Nguyen, DC, Kuruvilla, ME, et al. One-stop serum assay identifies COVID-19 disease severity and vaccination responses. Immunohorizons. 2021;5:322-335.
Google Scholar | Crossref | Medline25. Wang, Z, Schmidt, F, Weisblum, Y, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021;592:616-622.
Google Scholar | Crossref | Medline26. Bleier, BS, Ramanathan, M, Lane, AP. COVID-19 vaccines may not prevent nasal SARS-CoV-2 infection and asymptomatic transmission. Otolaryngol Head Neck Surg. 2021;164:305-307.
Google Scholar | SAGE Journals27. Nance, KD, Meier, JL. Modifications in an emergency: the role of N1-methylpseudouridine in COVID-19 vaccines. ACS Cent Sci. 2021;7:748-756.
Google Scholar | Crossref | Medline28. Corbett, KS, Flynn, B, Foulds, KE, et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in Nonhuman primates. New Engl J Med. 2020;383:1544-1555.
Google Scholar | Crossref | Medline29. Corbett, KS, Nason, MC, Flach, B, et al. Immune correlates of protection by mRNA-1273 immunization against SARS-CoV-2 infection in Nonhuman primates. bioRxiv. 2021.
Google Scholar30. Corbett, KS, Werner, AP, O’ Connell, S, et al. Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 infection in Nonhuman primates. bioRxiv. 2021.
Google Scholar31. Woldemeskel, BA, Garliss, CC, Blankson, JN. SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63. J Clin Investig. 2021;131: e149335. doi:10.1172/JCI149335.
Google Scholar | Crossref32. Reynolds, CJ, Pade, C, Gibbons, JM, et al. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science. Published online April 30, 2021. doi:10.1126/science.abh1282
Google Scholar | Crossref33. Sahin, U, Muik, A, Derhovanessian, E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586:594-599.
Google Scholar | Crossref | Medline